Characterizing mild cognitive impairment in incident Parkinson disease : The ICICLE-PD Study

Neurology

Volumn 82, Issue 4, 2014, Pages 308-316

  Yarnall, Alison J ^a   Breen, David P ^d   Duncan, Gordon W ^a   Khoo, Tien K ^j   Coleman, Shirley Y ^b   Firbank, Michael J ^a   Nombela, Cristina ^e,f,g   Winder Rhodes, Sophie ^e,f,g   Evans, Jonathan R ^d   Rowe, James B ^e,g   Mollenhauer, Brit ^e   Kruse, Niels ^k   Hudson, Gavin ^c   Chinnery, Patrick F ^c   O'Brien, John T ^h   Robbins, Trevor W ^f,i   Wesnes, Keith ^l   Brooks, David J ^m   Barker, Roger A ^d   Burn, David J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Industrial Statistics Research Unit   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e Department of Clinical Neurosciences ^*  (Germany)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

^h Departments of Psychiatry   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j GRIFFITH UNIVERSITY   (Australia)

^k UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^l SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^m IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMYLOID BETA PROTEIN[1-42]; LEVODOPA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; EDUCATION; FEMALE; GENETIC VARIABILITY; GENOTYPE; GRAY MATTER; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MOTOR DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PARKINSON DISEASE; PATTERN RECOGNITION; PRIORITY JOURNAL; VERY ELDERLY; VOXEL BASED MORPHOMETRY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 84895770516     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000066     Document Type: Article

References (40)

1. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov Disord 2008; 23:837-844.
2. Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:585-589.
3. Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 2009;73:1469-1477.
4. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-2969.
5. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.
6. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: Progression to dementia. Mov Disord 2006;21:1343-1349.
7. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: The Norwegian ParkWest study. JAMA Neurol 2013;70: 580-586.
8. Weintraub D, Dietz N, Duda JE, et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 2012;135:170-180.
9. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid b 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-1061.
10. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
11. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 2008;23: 2129-2170.
12. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427-442.
13. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1983;17:37-49.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": A practical method for grading cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
15. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
16. Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: A randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183-192.
17. Robbins TW, JamesM, Owen AM, Sahakian BJ,McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): A factor analytic study of a large sample of normal elderly volunteers. Dementia 1994;5:266-281.
18. Benton AL. Differential behavioural effects of frontal lobe disease. Neuropsychologia 1968;6:53-60.
19. Goodglass H. The Assessment of Aphasia and Related Disorders. Philadelphia: Lea & Febiger; 1972.
20. Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:483-488.
21. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology 2010;75:1062-1069.
22. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-1277.
23. Dalrymple-Alford JC, Livingston L, MacAskill MR, et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord 2011;26:629-636.
24. Poletti M, Frosini D, Pagni C, et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:601-606.
25. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G; Norwegian ParkWest Study Group. Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest study. Neurology 2009;72:1121-1126.
26. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK: The CamPaIGN study. Brain 2004;127:550-560.
27. Bronnick K, Alves G, Aarsland D, Tysnes OB, Larsen JP. Verbal memory in drug-naive, newly diagnosed Parkinson's disease: The retrieval deficit hypothesis revisited. Neuropsychology 2011;25:114-124.
28. Lashley T, Holton JL, Gray E, et al. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008; 115:417-425.
29. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-411.
30. Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24:2203-2210.
31. Montine TJ, Shi M, Quinn JF, et al. CSF Abeta (42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25:2682-2685.
32. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Betaamyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006;22:200-208.
33. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: The Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010;81:1080-1086.
34. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008; 64:850-855.
35. Adler CH, Caviness JN, SabbaghMN, et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120:827-828.
36. Reesink FE, Lemstra AW, van Dijk KD, et al. CSF alphasynuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis 2010;22:87-95.
37. El-Agnaf OM, Walsh DM, Allsop D. Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol 2003;2:461-462.
38. Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson's disease. Mov Disord 2012;27:512-518.
39. Melzer TR, Watts R, MacAskill MR, et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:188-194.
40. Dalaker TO, Zivadinov R, Larsen JP, et al. Gray matter correlations of cognition in incident Parkinson's disease. Mov Disord 2010;25:629-633.